[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632303":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":33,"responsibleParty":51,"collaborators":20,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":20,"maxAge":20,"enrollmentInfo":61,"targetDuration":20,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"The Netherlands Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Additional novel PET\u002FCT","EXPERIMENTAL","Additional novel PET\u002FCT scan compared to standard-of-care",[13],"Diagnostic Test: 86-Gallium PSMA PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","86-Gallium PSMA PET\u002FCT","PET\u002FCT 45 minutes after intravenous administration of 100MBq Gallium-68 labelled PSMA-11 (\\[68Ga\\]Ga-PSMA-11)",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Dieta Brandsma, MD, PhD","Antoni van Leeuwenhoek Ziekenhuis","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Lente Kroon, MD","CONTACT","0031205129111","neurologie@nki.nl",{"name":23,"role":29,"phone":20,"phoneExt":20,"email":20},[34],{"facility":35,"status":36,"city":37,"state":20,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Netherlands Cancer Institute - Antoni van Leeuwenhoek","RECRUITING","Amsterdam","1066 CX Amsterdam","Netherlands","NL",{"type":42,"coordinates":43},"Point",[44,45],4.88969,52.37403,{"lat":45,"lon":44},[48,50],{"name":28,"role":29,"phone":49,"phoneExt":20,"email":31},"0205129111",{"name":23,"role":29,"phone":20,"phoneExt":20,"email":20},{"type":52,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100632303","novel-ga68-psma-petct-tracer-to-differentiate-between-radiation-necrosis-and-tumor-progression-in-brain-metastases-100632303",false,"NCT07511933","Novel Ga68-PSMA PET\u002FCT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases","Novel Ga68-PSMA PET\u002FCT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Stereotactic Irradiated Brain Metastases. A Feasibility Study.","Inclusion Criteria:\n\nFor all groups:\n\n* Written informed consent\n* Age ≥ 18 years old\n* WHO PS 0-3\n* Measurable lesion ≥10mm according to RANO BM\n\nFor brain metastases groups:\n\n\\- newly diagnosed brain metastases from either NSCLC (group 1) or melanoma (group 2) or breast cancer (group 7).\n\nFor radiation necrosis groups:\n\n\\- Brain lesion at the location of a formerly brain metastases that has been treated with SRT (\\> 9 months ago), with the definite diagnosis of radiation necrosis at the location of formerly SRT-treated brain metastases of NSCLC (group 3), melanoma (group 4) and\u002F or breast cancer (group 8).\n\nFor diagnostic dilemma groups:\n\n\\- Brain lesion at the location of a formerly brain metastases with a diagnostic dilemma of radiation necrosis and recurrent brain metastases of NSCLC (group 5), melanoma (group 6) and\u002F or breast cancer (group 9).\n\nExclusion Criteria:\n\nFor all groups:\n\n* Known allergy to Ga68-PSMA\n* Epileptic seizure less than 7 days before Ga68-PSMA PET\u002FCT scan\n* Life expectancy less than 3 months\n* Patients with known prostate carcinoma\n* Pregnancy","ALL",{"count":62,"type":63},100,"ESTIMATED","INTERVENTIONAL",[66],"NA","This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET\u002FCT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.",[69,70,71],"Brain Metastases From Non-small Cell Lung Cancer (NSCLC)","Brain Metastases From Melanoma","Brain Metastases From Breast Cancer",[73,74,75,76],"Brain Metastases","Radiation Necrosis","Diagnostic Imaging","Radiation-induced Toxicity","2026-03-30",{"date":79,"type":80},"2026-04-06","ACTUAL",{"date":82,"type":80},"2019-12-24",{"date":84,"type":63},"2027-07-01",{"name":5,"class":6},1]